At a glance
- Originator Pfizer
- Class
- Mechanism of Action Immunosuppressants; Potassium channel antagonists; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 25 Jun 2000 No-Development-Reported for Immunosuppression in USA (Unknown route)
- 08 Dec 1997 Preclinical development for Immunosuppression in USA (Unknown route)
- 29 Sep 1997 New profile